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ABSTRACT
Purpose: Aerobic exercise (AE) lowers blood pressure (BP) 5-7 mmHg among those with hypertension,
but there is considerable variability in the BP response to AE. Genetic predispositions account for 40-65%
of this variability; however, identifying genetic variants that associate with the BP response to AE is a
challenge. We performed a meta-analysis to integrate the small number of studies that examined the
influence of candidate genes on the BP response to AE. Methods: Studies retrieved included an acute or
chronic AE intervention; BP before and after AE by genotype; and candidate gene polymorphisms. Effect
sizes were the standardized mean difference of BP post-vs. pre-exercise for AE training interventions, and
post-vs. pre-exercise BP vs. control for acute AE interventions. Effect sizes were disaggregated for
genotype and adjusted for baseline sample features. Analyses followed fixed-effects assumptions. Results:
11 AE training (N=2646) and 4 acute AE (N=50) studies qualified. AE training interventions were
performed at 62.3±7.5% (Mean+SD) maximum oxygen consumption for 43.8±11.6 min⋅session-1, 3.6±1.2
d⋅wk-1 for 15.3±7.6 wk. Participants were mostly non-Hispanic white (N=1,736) men (N=1,278) and
women (N=1,360), 44.2±10.7 yr with a BP of 134.4±11.9/78.6±9.3 mmHg and body mass index of
26.9±2.6 kg.m-2.The effect of exercise on the BP response to AE training was small but statistically
significant for systolic BP (SBP) (d+ = -0.21 [95% CI = -0.247, -0.168], -3.1 mmHg, I2=77.8%) and
diastolic BP (DBP) (d+ = -0.20 [95% CI = -0.235, -0.158], -1.9 mmHg, I2=62.2%). Sample features
explained 59.1-71.5% of the variability in the BP response to AE training (P< 0.001), and reductions were
greater among samples that had a higher resting BP (SBP: β = -0.68, P< 0.001; DBP: β=-0.56, P=0.01),
that were younger (SBP: β=0.34, P<0.01; DBP: NS, P>0.05), and that included more women than men
(SBP: β = 0.41, P<0.001; DBP: β=0.52, P<0.001. Only the angiotensinogen (AGT) M235T (rs699)
polymorphism showed a significant association with the DBP response to AE training (Multiple R=0.058,
P=0.02), explaining 0.3% of the variability in the DBP response. Pairwise comparisons of AGT M235T
genotypes showed those with the AGT MM genotype reduced DBP 2.9 mmHg more in response to AE
training compared to those with the AGT TT genotype (Multiple R=0.076, P=0.02). Acute interventions
were performed at 50.1±10.1% maximum oxygen consumption for 40 min·session-1. Participants were men,
44.1±1.0 yr with a BP of 145.7±1.7 / 85.8±0.9 mmHg and body mass index of 29.9±0.3 kg.m-2. BP
responses to acute AE were large and heterogeneous for SBP (d+ = -0.62 [95% CI = -0.75, -0.50], -5.5
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mmHg, I2 =48%), and small and homogeneous for DBP (d+ =-0.28 [95% CI = -0.40, -0.16], -1.7 mmHg, I2
=0%). Sample features explained 55.2-82.3% of the variability in the BP response to acute AE (P< 0.001),
while candidate gene polymorphisms explained a marginally significant 4.6-6.0% of the variability
(P=0.08). Analyses of individual polymorphisms were not feasible due to the low numbers of interventions
and observations. Conclusions: Despite our attempt to increase the sample size to detect polymorphism
associations with the BP response to AE, sample features explained most of the variability across trials,
although the AGT M235T polymorphism is promising. These findings reinforce the notion that most
genetic variants explain only a small amount of variability in the response of health/fitness phenotypes to
exercise, if any. Future research efforts seeking to explain the variability of health/fitness phenotypes to
exercise such as BP should explore sample features known to influence the phenotype of interest, as well as
the multiple levels of gene regulation using high throughput screening in larger, more ethnically diverse
samples of men and women with HTN.
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INTRODUCTION
Hypertension (HTN) is a major public health issue in the United States (US)
affecting an estimated 77.9 million US adults (33.3%) 20 years of age and older (Go et
al., 2013; JNC VII, 2003) [Table 1]. In addition, HTN is a major independent risk factor
for cardiovascular disease (CVD) and is the most common primary diagnosis in the US
(Go et al., 2013). The prevalence of HTN is higher in men (16.8%) than women (12.2%)
until 45 years, similar from 45 to 64 years (44.0%), and higher in women (75.5%) than
men (68.0%) after 64 years (Go et al., 2013). The prevalence among blacks (41.3%) is
higher than whites (28.9%), especially among black (47.0%) versus white (30.7%)
women (Go et al., 2013). Therefore, due to its significant impact on US public health, the
prevention, treatment, and control of HTN has become a major public health priority
(Pescatello, 2010).
Table 1: Classification of blood pressure among adults (JNC VII, 2003)

Blood Pressure Classification

SBP (mmHg)

DBP (mmHg)

< 120

and < 80

Prehypertension

120-139

or 80-89

Stage 1 Hypertension

140-159

or 90-99

Stage 2 Hypertension

A 160

or ≥ 100

Stage 3 Hypertension

≥ 180

or ≥ 110

Normal

Abbreviations. SBP, systolic blood pressure; DBP, diastolic blood pressure; mmHg, millimeters of mercury.

Aerobic exercise (AE) is an effective lifestyle therapy to prevent, treat, and
control HTN because it reduces BP 5-7 mmHg among those with HTN
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(Pescatello et. al., 2004). Evidence shows BP reductions of this magnitude can lower the
risk of developing CVD by 20-30% (JNC VII, 2003). Therefore, the American College of
Sports Medicine (ACSM) recommends a Frequency, Intensity, Time and Type (FITT)
exercise prescription (Ex Rx) for HTN of AE performed at moderate intensity (40-60% of
maximum oxygen reserve [VO2R]) for 30-60 minutes, on most preferably all days of the
week that is supplemented by resistance exercise (Pescatello et. al., 2004; Thompson,
Gordon, Pescatello, & American College of Sports Medicine, 2009).
Statement of the Problem
Despite the ACSM FITT Ex Rx to prevent, treat, and control HTN [Table 2],
there is considerable variation in the BP response to exercise, with 25% of the people
with HTN not lowering their BP with exercise (Hagberg, Park, & Brown, 2000).
Bouchard and Rankinen (2001) examined the inter-individual variation in the BP
response to a standardized 20 week AE training program among 481 sedentary, adult
Caucasians from 98 two-generation families as part of the HEalth, RIsk factors, exercise
Training And GEnetics (HERITAGE) family study. They found although there was an
average systolic BP (SBP) post training reduction of 8.2 ± 11.6 mmHg, a considerable
amount of heterogeneity remained with some subjects experiencing significant SBP
decreases (> 40 mmHg) and other subjects experiencing significant SBP increases (> 20
mmHg) (Bouchard & Rankinen, 2001; Bouchard et al., 2012). In addition, the standard
deviation of the mean BP response to AE training exceeded the mean value itself, further
supporting the inference of heterogeneity in the BP response to exercise. These findings
suggest that there are environmental and genetic components that contribute to the
inter-individual variation observed in the BP response to AE, with heritability estimates
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of approximately 40-65% across generations (Bouchard & Rankinen, 2001; Bouchard et
al., 2012).
Table 2: ACSM FITT Ex Rx for Hypertension (Thompson et al., 2009)
Frequency

On most, preferably all days of the week
700 - > 2,000 kcal·wk-1

Intensity

40-60% VO2R or HRR
64-84% HRmax
Borg RPE 11-14

Time

30-60 m·d-1 continuous or accumulated

Type

Aerobic supplemented by resistance exercise

Abbreviations. HRmax, heart rate max; HRR, heart rate reserve; kcal•wk-1, kilocalories per week; m•d-1, minutes
per day; RPE, rating of perceived exertion; VO2R, maximal oxygen consumption reserve.

Candidate gene studies aim to identify whether an association exists between a
specific genetic variant and health/fitness phenotype such as the BP response to exercise.
Presently, 26 different candidate gene polymorphisms have been reported to be
associated with the BP response to AE (Alioglu et al., 2010; Augeri et al., 2009;
Blanchard et al., 2006; Delmonico et al., 2005; de Luis et al., 2006; Feairheller et al.,
2009; Flavell et al., 2006; Franks et al., 2004; Friedl, Krempler, Sandhofer, & Paulweber,
1996 ;Grove et al., 2007; Hagberg, Ferrell, Dengel, & Wilund, 1999; Hautala et al., 2006;
Jones et al., 2006; Kilpelainen et al., 2008; Kimura et al., 2003; Macho-Azcarate, Marti,
Calabuig, & Martinez, 2002; Ortlepp et al., 2003; Pescatello et al., 2007a; Pescatello et
al., 2007b; Pescatello et al., 2009; Rankinen et al., 2000; Rankinen et al., 2002; Rankinen
et al., 2007; Rauramaa, et al. 2002; Rivera et al., 2001; Takakura et al., 2006; Vargas et
al., 2013; Zateyschikov, 2007 et al.; Zhang etal., 2002) [Appendix A]. These
polymorphisms include those involved with: 1) Renin Angiotensin System (RAS) and/or
11

Renal Function [angiotensin converting enzyme (ACE) (rs4340), adducin 1 alpha (ADD1)
(rs4961), angiotensinogen (AGT) (rs699), angiotensin 2 type 1 receptor (AGTR1)
(rs5186), and aldosterone synthase (CYP11B2) (rs1799998); 2) Sympathetic Nervous
System [adenosine monophosphate deaminase 1 (AMPD1) (rs17602729), adrenergic
receptor, beta 1 (ADRB1) (rs1801253), adrenergic receptor, beta 2 (ADRB2) (rs1042714),
cholinergic receptor (CHRM2) (rs324640, rs8191992), guanine nucleotide binding
protein system alpha subunit (GNAS) (rs7121), and guanine nucleotide binding protein,
beta polypeptide 3 (GNB3) (rs5443)]; and 3) Nitric Oxide Synthase Pathway and/or
Vascular Function [endothelin 1 (EDN1) (rs5370, rs2070699, rs5369), endothelial nitric
oxide synthase (NOS3) (rs2070744), and transforming growth factor, beta 1 (TGFB1)
(rs1800470)]. Other polymorphisms identified as established and emerging
cardiovascular disease risk factors implicated with the etiology of HTN include:1)
Dyslipidemia [apolipoprotein (APOE) (rs7412, rs429358), fatty acid binding protein 2
(FABP2) (rs1799883), and lipoprotein lipase (LPL) (rs328)]; 2) Obesity [leptin receptor
(LEPR) (rs1137100)]; and 3) Inflammatory Biomarkers [cytochrome b-245 alpha
polypeptide (CYBA) (rs4673, rs1049255), cytochrome P450 superfamily (CYP2D6)
(rs1065852), and interleukin 6 receptor (IL6R) (rs2228145).
Although these findings are promising, identifying specific genetic variants that
associate with the BP response to AE remains a significant challenge. Specifically, BP
candidate gene studies are limited by small sample sizes, a small number of common
single nucleotide polymorphisms (SNPs) examined, and lack of statistical correction for
multiple comparison testing. For these reasons, BP candidate gene association studies are
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plagued by a lack of replication, and ultimately, a large proportion of the variability in the
BP response to AE as related to genotype is left unexplained.
Meta-analysis systematically and quantitatively integrates the results of a body of
literature addressing a related hypothesis, ultimately increasing the sample size and
power to detect statistical differences (Bornstein, 2009). In addition, meta-analysis is able
to identify sources of diversity across different study designs and detect biases and
deficiencies in research (Ioannidis & Lau, 1999). Theoretically, meta-analysis should be
able to address some of the limitations of candidate gene association studies by
increasing the sample size to detect genotype/phenotype associations with the BP
response to AE.
In summary, 26 different candidate gene polymorphisms have been reported to be
associated with the BP response to AE. However, identifying specific genetic variants
accounting for the BP response variability remains a significant challenge due to the
limitations in candidate gene association studies examining the BP response to AE.
Theoretically, the use of meta-analysis should be able to increase the sample size of
current BP candidate gene studies to detect genotype/phenotype associations and provide
clearer insights regarding the role of genetic predispositions on the BP response to AE.
This study serves as the first meta- analysis to systematically and quantitatively integrate
the results of candidate gene association studies and the BP response to AE. In addition,
this study attempted to identify the specific genetic variants (if any) that associate with
the BP response to AE that can be explored in future work.
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Specific Aims & Hypotheses
The primary aim of this study was to perform a meta-analysis of candidate gene
association studies examining the BP response to AE. Through application of
meta-analytic procedures, this study intended to identify the overall and individual
genotype effect size values accounting for the variability in the BP response to AE.
Specific Aim 1: To determine the overall and individual genotype effect size values that
account for the missing BP response variability in AE.
Hypothesis 1: The overall and individual genotype effect size values on the BP response
to AE will be small to medium across studies.
Specific Aim 2: To disaggregate candidate gene polymorphisms based upon the number
of minor alleles (i.e., 0, 1, or 2) and to determine both the overall and individual additive
effect of candidate genes on the BP response to AE.
Hypothesis 2: As the number of minor alleles increase, the magnitude of the BP reduction
resulting from AE will be greater.
Specific Aim 3: To investigate the pairwise interactive effects of genotype
(i.e., 0 vs. 1, 0 vs. 2, and 1 vs. 2 minor alleles) within candidate gene polymorphisms and
the BP response to AE.
Hypothesis 3: Genotype groups with the greater number of minor alleles will reduce BP
in response to AE more than will genotype groups with the greater number of common
alleles.
Specific Aim 4: To examine the moderating effects of study level sample features
(i.e., age, gender, BMI, pre-exercise BP) on the BP response to AE.
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Hypothesis 4: Candidate gene polymorphisms will better predict the unexplained
variability in the BP response to AE than will study level sample features.
METHODS
This chapter outlines the methods used to perform this meta-analysis. In
particular, this chapter first discusses the literature search strategy that was used to gather
relevant studies for this meta-analysis. Then, the predetermined inclusion/exclusion
criteria, study outcome measure(s), and specific meta-analytic and statistical procedures
used to perform this meta-analysis will be discussed.
Literature Search
Search methods for identifying relevant studies
A systematic search was conducted using the following electronic databases:
MEDLINE (to April 2013), Biosis (to April 2013), Scopus (to April 2013), and Web of
Science (to April 2013). The keywords “blood pressure,” “exercise,” “randomized
control trial,” and “genes” were used in combination with medical subject heading
(MeSH) descriptors to search the databases for relevant studies [Table 3, Appendix B].
Article citation lists were also reviewed to identify additional studies. No language
restrictions were applied when attempting to locate studies for inclusion in this
meta-analysis.
The studies produced from the systematic search were screened via title and
abstract by two coders (MLB, KAL) for inclusion/exclusion criteria. To confirm the
accuracy of the screening process, the coders re-screened all studies that were initially
excluded to check for subtle errors (e.g., identifying excluded studies meeting the
predetermined inclusion criteria). Studies were included if they: 1) involved an acute
15

(response to a single bout of exercise) or chronic (response to training) AE intervention;
2) measured pre- and post-AE BP by genotype; 3) examined at least one candidate gene
polymorphism for association with the BP response to AE; and 4) contained a
case-control, cross-sectional, or family based study design. Studies were excluded if they:
1) involved animal or non-human models; 2) included literature lacking a peer review
process; or 3) examined the BP response to AE without a candidate gene polymorphism
such as in heritability or linkage studies [Appendix C].
Table 3. Keywords used in the literature search.
Blood Pressure-Keywords
Mean Arterial
Blood Pressure(s)
Arterial Pressure(s)
Hypertension
Hypotension
Normotension
Hypertensive
Hypotensive
Normotensive
Systolic Pressure
Diastolic Pressure
Pulse Pressure
Venous Pressure
Pressure Monitor
Pre-Hypertension
Blood Pressure Response
Blood Pressure Decrease
Blood Pressure Reduction
Blood Pressure Monitor(s)
Blood Pressure Measurement

Genetic-Keywords
Gene(s)
Genotype(s)
Single Nucleotide Polymorphism(s)
Polymorphism
Deoxyribonucleic Acid
Minor Allele(s)
Genetic

Exercise-Keywords
Exercise(s)
Running
Cycle(s)
Cycling
Walking
Treadmill
Endurance Training
Weight Training
Speed Training
Training Duration
Training Frequency
Training Intensity
Aerobic Endurance

All words used in: title, original title, substance word, subject heading word, and abstract. Randomized control trial (RCT) filter
applied in all search commands

Types of participants
Study participants involved adults’ ≥19 years. The participants were of any
gender, ethnicity, body composition, BP classification, or physical activity status. In
addition, the included participants may have had a family history of heart disease or
16

HTN, possessed a known disease or chronic condition(s) related to CVD (e.g., congestive
heart failure, metabolic syndrome [MetS]), or consumed prescribed BP medication of any
kind. Excluded participants possessed known disease or chronic health conditions
unrelated to CVD (e.g., cancer, neoplasms, fibromyalgia, Alzheimer’s, pregnancy,
epilepsy, pneumonia, septicemia, HIV, AIDS, and meningitis). In addition, study
participants consuming prescribed BP medications that did not undergo a sufficient
washout period prior to exercise were excluded. All coded descriptive participant
variables are listed within the comprehensive coding form [Appendix D].
Types of interventions
Only acute and chronic AE interventions were included in the meta-analysis.
Acute studies must have compared an exercise intervention group to either a non-exercise
control group or a control session. Chronic studies must have compared an exercise
intervention group to either a non-exercise control group or control session (if possible),
or compared an exercise intervention group cross-sectionally by genotype(s). The
exercise interventions were permitted to occur in any setting—hospital, clinic, academic
research laboratory, fitness center, or other venue. Exercise interventions were delivered
via one-to-one (e.g., personal training) or in groups, and were supervised or
unsupervised. All descriptive intervention variables that were coded are listed within the
comprehensive coding form [Appendix D].
Outcome measure
The primary goal of this meta-analysis was to determine the overall and
individual genotype effect size values accounting for the variability in the BP response to
AE. The overall effect size estimate was measured using Becker’s d to quantify the
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magnitude of BP change (across all polymorphisms) in response to exercise. Becker’s d
was computed as the post- vs. pre-exercise BP response divided by the pre-exercise
standard deviation. The effect size estimates were then disaggregated by genotype for
each polymorphism examined, yielding either two (dominant or recessive models) or
three (co-dominant or additive models) d values for each study (Becker, 1988). Negative
values of d implied BP was lower at post- versus pre-exercise, thereby demonstrating a
favorable response to exercise.
Data extraction
After screening potential articles for inclusion/exclusion criteria via title and
abstract, the remaining studies underwent a full-text review. Studies that continued to
fulfill the inclusion/exclusion criteria were subject to data extraction via a 246-item
coding form [Appendix D]. Two coders (MLB, KAL) independently performed the data
extraction procedures; the coders were trained from an expert in meta-analysis (TBH-M)
with 10 pilot studies to ensure accurate and reliable interpretation of coded studies. The
coders then reviewed the 10 pilot studies with the meta-analytic expert and resolved
discrepancies in coding. If a consensus could not be reached, a third coder mediated
unresolved discrepancies. Once an inter-rater reliability of 0.80 was reached on the
sampled pilot studies, the coders then coded the remaining included studies. The coders
continued to meet weekly to review the coded studies and compare coded data
line-by-line, continuing to address any questions, concerns or issues encountered
throughout the data extraction process. Extracted study and subject data included
variables related to: age, body mass index (BMI), baseline or pre-exercise systolic (SBP)
and diastolic (DBP) BP, gender, ethnicity, study quality, and geographical region or
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population. Extensive and detailed study, subject, and intervention variables were coded
on the comprehensive coding form [Appendix D].
Study Quality
Study quality was assessed with the Down and Black’s (1998) methodological
quality checklist, a 27-item questionnaire with items in the five general domains of: 1)
the appropriateness of assessing randomized and non-randomized control trials; 2) the
provision of computing both an overall score for study quality and a profile of scores not
only for the quality of reporting; 3) internal validity (bias and confounding); 4) external
validity; and 5) power [Appendix D].
Data extraction agreement
A Kappa statistic was computed to assess inter-coder reliability for categorical
variables. The Kappa statistic is interpreted as follows: < 0.00 = poor, 0.00-0.20 = slight,
0.21-0.40 = fair, 0.41-0.60 = moderate, 0.61-0.80 = substantial and 0.81-1.00 = almost
perfect agreement between coders (Meyer, 1999). The Pearson’s r correlation is a
statistical measure that ranges in value from +1 and -1, and accounts for the percent of
between rater agreements for a given variable. The Pearson r correlation is interpreted as
follows: ≤ -0.70 = very strong negative relationship, -0.40 to -0.69 = strong negative
relationship, -0.30 to -0.39 = moderate negative relationship, -0.20 to -0.29 = weak
negative relationship, -0.01 to -0.19 = no or negligible relationship, +0.01 to +0.19 = no
or negligible relationship, +0.20 to +0.29 = weak positive relationship, +0.30 to +0.39 =
moderate positive relationship, +0.40 to +0.69 = strong positive relationship, ≥ +0.70 =
very strong positive agreement. Reliability was assessed regularly during the coding of
studies (every 2 weeks) to ensure that inter-coder agreement remained at high levels.
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Effect Size Estimate
The overall effect size estimate was computed using Becker’s d to quantify the
magnitude of BP change (across all polymorphisms) in response to exercise. Becker’s d
was computed as the post- vs. pre-exercise BP response divided by the pre-exercise
standard deviation (Becker, 1998). The effect size estimates were then disaggregated by
genotype for each polymorphism examined. The purpose of this procedure was to
quantify the individual effect size estimate of each genotype for every polymorphism
examined for every intervention arm of each study. Therefore, there were either two
(dominant or recessive models) or three (co-dominant or additive models) d values for
each study intervention (Becker, 1988). Acute studies were computed as the post- vs.
pre-exercise BP response compared to control while chronic studies were computed with
no control comparison. Negative values of d implied BP was lower at post- versus
pre-exercise, implying a favorable response to exercise.
Average Effect Size Calculation (Fixed Effects vs. Random Effects)
Fixed Effects Modeling
Analyses followed fixed-effects assumptions because studies meeting our
predetermined inclusion/exclusion criteria were of small quantity and therefore offered
low precision in estimating population variation in effects. Fixed-effects models assume
that all studies in a meta-analysis share a common effect size (Borenstein, 2009). Each
effect size value was assigned a weight that corresponded to the inverse study variance.
Random Effects Modeling
Random effects modeling, like fixed effects modeling, is weighted by the inverse
study variance. However, random effects modeling also factors between-study variance
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into the estimate of the constant, denoted as τ2 (tau-squared). The random-effects model
assumes that there are uncontrolled factors influencing the effect sizes of the studies’
observed. Under heterogeneity, such models provide wider confidence intervals around
mean effect sizes, reflecting a relatively conservative analytic approach (Bornstein,
2009). However, because the number of studies meeting our predetermined
inclusion/exclusion criteria was small, the random effects model was not used in the
meta-analysis (Bornstein, 2009).
Publication Bias
Potential for publication bias was assessed graphically via forest plots and funnel
plots, and statistically via Begg’s and Egger’s methods (Beggs & Mazumder, 1994;
Borenstein, 2009; Egger, Davey Smith, Scneider, & Minder, 1997). Tests for publication
bias assume that asymmetries in the distribution of effect size estimates imply publication
biases. As a result, forest plots illustrate the variability of an effect size between sampled
studies, while funnel plots depict an effect size across sampled studies by plotting an
effect size against its variance (Borenstein, 2009). The graphical presence of publication
bias was identified as an asymmetrical funnel shape in a funnel plot, while symmetrical
funnel shapes indicated the absence of publication bias (Borenstein, 2009). If publication
bias was present in the meta-analysis, the “Trim and Fill” method was used (Duval &
Tweedie, 2000). The “Trim and Fill” method provides a statistically unbiased pooled
estimate of study effects with varying results by imputing the presence of missing studies
(Duval & Tweedie, 2000).
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Heterogeneity
The Q (unstandardized) and I2 (standardized)statistics were used to determine if
the between-study variance exceeded what would be expected on the basis of sampling
error alone, justifying an inference of heterogeneity (Higgins & Thompson, 2002;
Huedo-Medina, Sanchez-Meca, Marin-Martinez, & Botella, 2006). The Q statistic is an
unstandardized inference of homogeneity, making it difficult to interpret in meta-analysis
(Higgins & Thompson, 2002). Therefore, the I2 statistic was indexed on the basis of Q to
assess homogeneity (Huedo-Medina et al., 2006). I2 values range from 0-100%, with
values closer to 0% indicating homogeneity (studies exhibit a similar or homogenous
pattern) and values closer to 100% indicating heterogeneity (studies exhibit a dissimilar
or heterogeneous pattern) between study effect sizes (Huedo-Medina et al., 2006).
Meta-Regression
Moderator (i.e., covariate) analyses were examined using bivariate and
multivariate meta-regression techniques to determine their influence on the BP response
to AE. Analyses first controlled for clinical sample characteristics (i.e., age, BMI, gender,
and pre-exercise BP) and then examined whether genotype BP associations explain the
unique variation in ds. Candidate gene meta-regression analyses followed an additive
model to determine the linear trends of genotype by the number of minor alleles in a
given polymorphism. When there were at least nine effect size observances (cases) for a
given candidate gene polymorphism, meta-regressions were also used to compare each
pair of possible genotype combinations (i.e., 0 vs. 1, 0 vs. 2, and 1 vs. 2 minor alleles). If
a significant genotype BP association appeared on a bivariate basis for a particular
polymorphism, the polymorphism was then evaluated against the entire set of ds in the
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multivariate model. Specifically, an interaction term was computed to determine whether
the associated polymorphism differed significantly from all other polymorphisms in the
model. The moving constant technique was used to estimate d for different genotypes that
meta-regression models linked to the BP response to AE (Johnson & Huedo-Medina,
2011). The moving constant technique illuminates patterns in multivariate regression
models by estimating both effect size values and confidence intervals at moderator levels
of interest and the meta-regression line itself (Johnson & Huedo-Medina, 2011). To
control for simultaneous statistical tests, a Bonferroni-corrected α-level of p ≤. 03 (k=44)
was used for dominant/recessive models with two genotype groupings and p ≤.02
(k=286) was used for co-dominant/additive models with three genotype groupings (Abdi
& Valentin, 2007).
Statistical Computing
Analyses were completed using Stata version 11.1 with macros (i.e., meanes,
metareg, metaf, metan, metabias, and confunnel) for meta-analysis (StataCorp, 2009;
Lipsey & Wilson, 2001; Wilson, 2001; Harris et al., 2008; Sterne, Harris, Harbord,
Steichen, 2009). Data extraction agreement was completed using the Statistical Package
for the Social Sciences and a Microsoft Excel Kappa statistic calculator (SPSS Inc., 2005;
Huedo-Medina & Johnson, 2011). Individual effect size estimates were completed with a
Microsoft Excel calculator (Huedo-Medina & Johnson, 2011).
Limitations
Meta-analysis synthesizes prior empirical evidence and is therefore subject to the
limitations of the literature it examines. Individual study quality of included trials can
significantly impact the quality of the meta-analysis. To control for individual study
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quality, a rigorous inclusion/exclusion criteria was used to screen relevant studies, and
individual study quality was assessed with the Downs and Black methodological quality
checklist (Downs & Black, 1998). In addition, study quality was examined as a
moderating variable in meta-regression analyses to determine whether higher quality
studies yield differing results from lower quality studies.
Secondly, because we examined published articles, our findings may have been
subject to publication bias (Bornstein, 2009). We searched multiple databases and used
broad search terminology when attempting to locate as many possible articles relating to
the meta-analysis. However, there is the possibility that some studies were not located,
perhaps skewing our effect size results. Therefore, publication bias was assessed
graphically with funnel and forest plots, as well as with statistical procedures (i.e., Begg
& Egger tests) to correct for publication bias when present (Borenstein, 2009).
Lastly, data extraction may also be a source of limitation. Despite training, a
comprehensive coding form, and performing multiple pilot tests, subtle errors were still
possible when coding large amounts of literature. To limit coding error, we used two
coders. Coders were trained from an expert in meta-analysis (TBH-M) with 10 pilot
studies. If discrepancies in coding could not be resolved, a third coder was used to
mediate. Once an inter-rater reliability of 0.80 was reached on the 10 sampled pilot
studies, coders began coding. Coders met weekly to review all coded studies, comparing
answers line-by-line, and addressing any questions, concerns, or issues encountered
throughout the data extraction process. In addition, data extraction agreement was
assessed at weeks 2, 4, 6, and 8 to confirm inter-rater reliability across coded studies.
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Delimitations
The primary goal of this meta-analysis was to identify the most relevant candidate
genes associated with the BP response to AE. This study did not intend to affirm
causation among candidate genes and the BP response to AE; rather, it aimed to elucidate
which genetic variants may be associated to the BP response to AE. In addition, this
meta-analysis attempted to circumvent the limitations of candidate gene association
studies examining the response of health/fitness phenotypes to exercise by increasing the
sample size needed to detect genotype and health/fitness phenotype associations. The
information gained from this meta-analysis provides insight to exercise scientists
examining the response variability of health/fitness phenotypes to exercise by
determining the emergence of promising candidate gene polymorphisms that should be
explored in future research.
Clinical Significance & Application
The findings of our meta-analysis provide exercise scientists with new
information on the role genetic predispositions might pose on the BP response to AE.
New knowledge gained from this study may be useful in refining the Ex Rx for HTN by
identifying candidate genes that may and may not influence the BP response to AE. This
information can also be used to better tailor individualized Ex Rx for those who do and
do not respond to AE as a therapeutic modality to prevent, treat, and control HTN. In
addition, a better understanding of how genetic predispositions modulate the
antihypertensive effects of AE may provide biological insight into the regulatory
pathways of the BP response to AE, and perhaps the pathophysiology of HTN.
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RESULTS
Aerobic Exercise Training
Study Characteristics
There were 523 potentially relevant studies retrieved. Of these, 11 (N=2,646)
studies met the predetermined inclusion/exclusion criteria and examined ten candidate
gene polymorphisms (Feairheller et al., 2009; Flavell et al., 2006; Hautala et al., 2006;
Jones et al., 2006; Rankinen et al., 2000; Rankinen et al., 2002; Rauramaa et al., 2002;
Rivera et al., 2001; Takakura et al., 2002; Vargas et al., 2013; Zhang et al., 2002)
[Figure 1]. The ten candidate gene polymorphisms examined were: angiotensin
converting enzyme (ACE) (rs4340) (k=3), angiotensinogen (AGT) (rs699) (k=4),
cholinergic receptor (CHRM2) (rs324640, rs8191992) (k=1), cytochrome b-245 alpha
polypeptide (CYBA) (rs4673, rs1049255) (k=1), guanine nucleotide binding protein, beta
polypeptide 3 (GNB3) (rs5443) (k=1), interleukin 6 receptor (IL6R) (rs2228145) (k=1),
lipoprotein lipase (LPL) (rs328) (k=1), and transforming growth factor, beta 1 (TGFB1)
(rs1800470) (k=1).
In total, 59 effect size estimates were computed for SBP and DBP, yielding 118
effect size estimates. Studies were completed in the US (45%), UK (27%), Japan (18%),
and South America (9%) with the exercise interventions completed in academic research
laboratories (82%) and/or university hospitals (18%). The average study quality score
was 15.2±2.1 out of a possible 26 points on the Downs and Black (1998) scale, indicating
poor to average study quality.
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Study Characteristics
Subjects were mostly middle aged (44.2±10.7 yr), overweight (26.9±2.6 kg⋅m-2)
non-Hispanic white (N=1,764) men (N=1,288) and women (N=1,358) with pre-HTN
(134.4±11.9/78.6±9.3 mmHg).
Aerobic Exercise Intervention Characteristics
Aerobic exercise (AE) interventions were performed at an average vigorous
intensity of 62.3±7.5% VO2max for 43.8±11.6 min⋅session-1, 3.6±1.2 d⋅wk-1 for 15.3±7.6
wk. AE modalities included stationary cycling (k=6), walking (k=3), and two not
specified. Participants were supervised by a trained exercise professional in seven AE
interventions, unsupervised in two, and not reported in two. Exercise adherence was
reported in only three of the AE interventions, with a mean adherence rate of 87.6±1.1%.
The BP Response to Aerobic Exercise Training
The weighted mean effect size (d+) for the change in BP after versus before AE
training was small but statistically significant (SBP d+= -0.21 [95% CI= -0.247, -0.168],
-3.1 mmHg, I2=77.8%; and DBP d+= -0.20 [95% CI= -0.235, -0.158], -1.9 mmHg,
I2=62.2%).
Multi-Predictor Analyses
Sample Features Associated with the BP Response to Aerobic Exercise Training
Sample features explained a large portion of the variance in the BP response to
AE training, 71.5% for SBP (Multiple R=0.845, P<0.001) and 59.1% for DBP (Multiple
R=0.769, P<0.001) [Tables 4 & 5]. Reductions in SBP after versus before AE training
were greater in samples with higher resting SBP (β=-0.68, P<0.001); that were younger
(β=0.34, P<0.01); and that included more women than men (β=0.41, P<0.001). For, SBP
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decreased 8.8 mmHg among those with HTN, d+= -0.56 [95% CI= -0.644, -0.469], and
3.0 mmHg among those with Pre-HTN, d+= -0.20 [95% CI= -0.250, -0.158], while SBP
increased 2.5 mmHg among those with normal BP, d+=0.13 [95% CI=0.044, 0.211]. SBP
decreased 8.8 mmHg among young adults, d+= -0.50 [95% CI= -0.625, -0.374], and 3.1
mmHg among middle-aged adults, d+= -0.22 [95% CI= -0.262, -0.169], while SBP
increased 0.3 mmHg among older adults, d+= -0.04 [95% CI= -0.156, 0.074]. Lastly,
SBP decreased 8.4 mmHg among samples containing women only, d+= -0.55 [95% CI=
-0.669, -0.422], and 3.0 mmHg among samples containing approximately equal numbers
of women and men, d+= -0.20 [95% CI= -0.250, -0.156], while SBP increased 2.6 mmHg
among samples containing men only, d+=0.15 [95% CI= 0.012, 0.282].
Reductions in DBP after versus before training were greater in samples with
higher resting DBP (β= -0.56, P=0.01); and that included more women than men (β=0.52,
P<0.001). For, DBP decreased 5.3 mmHg among those with HTN, d+= -0.49 [95% CI=
-0.651, -0.332], and 2.3 mmHg among those with Pre-HTN, d+= -0.23 [95% CI= -0.276,
-0.183], while DBP increased 0.5 mmHg among those with normal BP, d+=0.01 [95%
CI= -0.120, 0.131]. DBP decreased 5.4 mmHg among samples containing women only,
d+= -0.55 [95% CI= -0.660, -0.436], and 2.2 mmHg among samples containing
approximately equal numbers of women and men, d+= -0.22 [95% CI= -0.269, -0.175],
while DBP increased 1.0 mmHg among samples containing men only, d+=0.10 [95% CI=
-0.026, 0.220]. Age was not a significant correlate of the DBP response to AE training
(P>0.05).
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Candidate Gene Associations with the BP Response to Aerobic Exercise Training
AGT M235T (rs699) significantly associated with the DBP response to AE
training in the additive model of genotype association (Multiple R=0.058, P=0.02)
[Table 4]. Specifically, the reduction in DBP was greater among individuals with the
AGT MM genotype (N= 174) (d+= -0.53 [95% CI= -0.684, -0.374], -5.6 mmHg)
compared to those with the AGT TT genotype (N=179) (d+= -0.23 [95% CI= -0.389,
-0.064], -2.7 mmHg) after versus before AE training [Table 5]. No parallel effects were
found with the AGT M235T polymorphism and the SBP response to AE training
(P=0.82). In addition, none of the nine other candidate polymorphisms significantly
associated with either the SBP or DBP response to AE training (P>0.05).
Acute Aerobic Exercise
Study Characteristics
There were 523 potentially relevant studies retrieved. Of these, four studies met
the predetermined inclusion/exclusion criteria and examined six candidate gene
polymorphisms (Augeri et al., 2009; Blanchard et al., 2006; Pescatello et al., 2007a,
2009) [Figure 2]. The six candidate gene polymorphisms that were examined were:
angiotensin converting enzyme (ACE) (rs4340) (k=1), adducin 1 (alpha) (ADD1) (rs4961)
(k=1), angiotensin 2 type I receptor (AGTR1) (rs5186) (k=1), aldosterone synthase
(CYP11B2) (rs1799998) (k=1), guanine nucleotide binding protein system alpha subunit
(GNAS) (rs7121) (k=1), and endothelial nitric oxide synthase (NOS3) (rs2070744) (k=1).
In total, 128 effect size estimates were computed; 32 for SBP and DBP versus control to
total 64 effect size estimates, plus 32 for the two experimental conditions to total 64
effect size estimates. All interventions were conducted in the US and in one laboratory.
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The average study quality score was 18.2±2.4 out of a possible 26 points on the Downs
and Black (1998) scale, indicating moderate to good study quality.
Study Participants
Subjects were middle aged (44.1±1.0 yr), overweight (29.9±0.3 kg⋅m-2)
non-Hispanic white (N=50) men with HTN (145.7±1.7/85.8±0.9 mmHg).
Aerobic Exercise Intervention Characteristics
The aerobic exercise (AE) intervention involved acute cycle exercise performed at
light (40% VO2peak) and moderate (60% VO2peak) intensity for 40 min⋅session-1. All
participants were supervised by a trained exercise professional and were adherent to the
AE intervention.
The BP Response to Acute Aerobic Exercise
The weighted mean effect size (d+) for the change in BP after versus before acute
AE compared to control was large for SBP (d+= -0.62 [95% CI= -0.745, -0.504], -5.5
mmHg, I2=48%), and small for DBP (d+= -0.28 [95% CI= -0.398, -0.162], -1.7 mmHg,
I2=0%).
Multi-Predictor Analyses
Sample Features Associated with the BP Response to Acute Aerobic Exercise
Sample features explained a large portion of the variance in the BP response to
acute AE for SBP (Multiple R=0.907, P<0.001), accounting for 82.3% of the variability
in the SBP response. Sample features explained 55.2% of the DBP response to acute AE
(Multiple R=0.743, P=0.12); however, this correlation did not achieve statistical
significance [Table 6]. Univariate analyses were unable to determine which sample
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feature(s) explained most of the variability in the SBP response to acute AE because all
studies involved participants from the same sample.
Candidate Gene Associations with the BP Response to Acute Aerobic Exercise
Beyond the influence of sample features, candidate genes explained 4.6% of the
variance in the SBP response to acute AE (Multiple R=0.214, P=0.08), a trend
approaching significance. Similarly, candidate genes explained 6.0% of the variance in
the DBP response to acute AE (Multiple R=0.245, P=0.08), a trend approaching
significance. The analyses of individual polymorphisms were not feasible due to the low
number of interventions and observations, and because all studies were derived from a
single trial, making non-independence a potential threat.
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Table 4. Blood pressure response to aerobic exercise training attributable to sample features
and candidate genes, where the linear trends of candidate gene minor alleles comprised a test
of the additive model of gene association.
Sample features’ association
Candidate gene association
a
with BP response to AE
with BP response to AEb
Candidate gene(s)
k
Multiple R
p
k Multiple R ∆
pc
SBP
All
59
0.845
<0.001†
59
0.120
0.22
ACE
AGT
All
ACE
AGT

15
15

0.790
0.926

59
15
15

15
15

0.396
0.116

0.64
0.82

0.769

0.08
<0.001†
DBP
<0.001†

59

0.108

0.20

0.759
0.890

0.10
<0.001†

15
15

0.159
0.058

0.07
0.02†

Note 1. Models in each row are somewhat independent of the models in the other rows.
Note 2. Univariate sample feature analyses do not appear in this table since the focus of the analysis was on candidate gene polymorphisms.
Note 3. The term All under candidate gene(s) is the aggregate model of all nine candidate gene polymorphisms examined in this meta-analysis.
Abbreviations. AE=aerobic exercise. BP=blood pressure. ∆=change. DBP=diastolic blood pressure. †=statistically significant association.
RAS=renin angiotensin system. SBP=systolic blood pressure. Gene abbreviations. ACE= angiotensin converting enzyme.
AGT=angiotensinogen.
a
Competing variables are mean sample age, proportion male, mean BMI, and mean SBP prior to exercise.
b
These models control for the competing variables, where possible.
c
Bonferroni adjusted p-value set at p≤.02.
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Table 5. Blood pressure response to aerobic exercise training attributable to sample features and
candidate genes, where pair-wise comparisons of genotype were made.
Sample features’ association
Candidate gene association
with BP response to AEa
with BP response to AEb
Candidate gene(s)
k
Multiple R
p
k Multiple R ∆
pd
SBP
All trials
CC vs. MM
37
0.835
<0.001†
37
0.175
0.41
CM vs. MM
38
0.837
<0.001†
38
0.159
0.28
†
CC vs. CM
37
0.848
<0.001
37
0.001
0.60
Gene-specific comparisons for studies with independent replicationsc
AGT
10
0.211
0.38
MM vs. TT
10
0.863
<0.001†
MT vs. TT
11
0.958
<0.001†
11
0.232
0.76
†
MM vs. MT
9
0.976
<0.001
9
0.111
0.91
DBP
All trials
CC vs. MM
37
0.569
<0.001†
37
0.153
0.81
†
CM vs. MM
38
0.572
<0.001
38
0.128
0.95
CC vs. CM
37
0.682
<0.001†
37
0.001
0.46
c
Gene-specific comparisons for studies with independent replications
AGT
10
0.076
0.02†
MM vs. TT
10
0.822
<0.01†
MT vs. TT
11
0.929
<0.001†
11
0.093
0.05
MM vs. MT
9
0.949
<0.001†
9
0.221
0.32
Note 1. Models in each row are somewhat independent of the models in the other rows.
Note 2. Univariate sample feature analyses do not appear in this table since the focus of the analysis was on candidate gene polymorphisms.
Note 3. The term All trials under candidate gene(s) refers to the pair-wise aggregate models of all nine candidate gene polymorphisms examined in
this meta-analysis.
Abbreviations. AE=aerobic exercise. BP=blood pressure. ∆=change. DBP=diastolic blood pressure. †=statistically significant association.
RAS=renin angiotensin system. SBP=systolic blood pressure. Gene abbreviations. ACE=angiotensin converting enzyme. AGT=angiotensinogen.
a
Competing variables are mean sample age, proportion male, mean BMI, and mean SBP prior to exercise.
b
These models control for the competing variables, where possible.
c

Only one study was available for the genes CYBA, CHRM2, GNB3, IL6R, LPL, and TGFB1. dBonferroni adjusted p-value set at
p≤02.
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Table 6. Ambulatory blood pressure response to acute aerobic exercise compared to control, attributable to
sample features and candidate genes.
Sample characteristics association
Candidate gene association
with BP response to AEa
with BP response to AEb
k
Multiple R
p
k
Multiple R ∆
pc
Blood Pressure
SBP

24

0.907

DBP

24

0.743

<0.001†
0.27

24

0.214

0.08

24

0.245

0.08

Note 1. Models in each row are somewhat independent of the models in the other rows.
Note 2. Univariate sample feature analyses do not appear in this table since the focus of the analysis was on candidate gene polymorphisms.
Note 3. All six-candidate gene polymorphisms are shown in aggregate form since there were not enough degrees of freedom to perform individual polymorphism analyses.
Abbreviations. AE=aerobic exercise. BP=blood pressure. ∆=change. DBP=diastolic blood pressure. †=statistically significant association. SBP=systolic blood pressure.
a
Variables included: mean sample age, proportion male, BMI, and BP prior to exercise.
b
These models control for the competing variables, where possible.
c
Bonferroni adjusted p-value set at p≤.03.
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Figure 1. Flow Diagram of Trial Identification and Selection for Aerobic Exercise Training
Potentially relevant trials
(k=523)

Trials excluded (k=403)
1. No use of exercise
2. No use of genetics
3. No examination of BP
4. Targeted animal/non-human models
5. Non-peer reviewed publication

Retrieved trials (k=120)

Trials excluded (k=40)
1. Twin studies without examination of a candidate gene
2. Heritability studies without examination of a candidate gene
3. Family-based studies without examination of a candidate gene
Potentially appropriate
trials (k=80)
Trials excluded (k=69)
1. No AE intervention
2. No pre/post BP measurement by genotype
3. No candidate gene polymorphism examined

Trials included in final
analysis (k=11)

Effect sizes calculated in final analysis (k=118)
1. SBP (k=59)
2. DBP (k=59)
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Figure 2. Flow Diagram of Trial Identification and Selection for Acute Aerobic Exercise
Potentially relevant trials
(k=523)

Trials excluded (k=403)
1. No use of exercise
2. No use of genetics
3. No examination of BP
4. Targeted animal/non-human models
5. Non-peer reviewed publication

Retrieved trials (k=120)

Trials excluded (k=40)
1. Twin studies without examination of a candidate gene
2. Heritability studies without examination of a candidate gene
3. Family-based studies without examination of a candidate gene
Potentially appropriate
trials (k=80)
Trials excluded (k=76)
1. No AE intervention
2. No pre/post BP measurement by genotype
3. No candidate gene polymorphism examined
4. No control group/session included
Trials included in final
analysis (k=4)

Effect sizes calculated in final analysis (k=128)
1. SBP 40% VO2peak (k=32)
2. DBP 40% VO2peak (k=32)
3. SBP 60% VO2peak (k=32)
4. DBP 60% VO2peak (k=32)
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DISCUSSION
The purpose of this meta-analysis was to examine the effects of candidate gene
polymorphisms on the BP response to aerobic exercise (AE). We also investigated patient
characteristics that influenced the BP response to AE. The major findings of this
meta-analysis were clinical sample features, rather than candidate gene polymorphisms,
explained most of the variability in the BP response to AE. Collectively, age (SBP 0.6%;
DBP 3.0%), gender (SBP 30.6%; DBP 23.1%) and resting BP (SBP 51.2%; DBP 8.1%)
accounted for 82.4% of the SBP and 34.2% of the DBP response to AE training.
Subgroup analyses of these sample features showed BP reductions were greater in
samples that were younger, that included more women than men, and that had a higher
pre-exercise resting BP. SBP was reduced 5.7 mmHg and 9.1 mmHg more among
younger than middle-aged and older adults, respectively. SBP and DBP were reduced
5.4/3.2 mmHg and 11.0/6.4 mmHg more among women than gender mixed samples and
samples with men only, respectively. Finally, SBP and DBP were reduced 5.8/3.0 mmHg
and 11.3/5.8 mmHg more among persons with HTN than persons with prehypertension
(pre-HTN) and normal BP, respectively.
In contrast to the significant proportion of variance in the BP response to AE
explained by clinical sample features, the overall contribution of candidate gene
polymorphisms on the BP response to AE training was small and non-significant. In fact,
only the AGT M235T single nucleotide polymorphism showed a significant association
with the DBP response to AE training, yet we found it to explain only 0.3% of the
variability in the DBP response. Pairwise comparisons of AGT M235T genotypes
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revealed those with the MM genotype reduced DBP 2.9 mmHg more in response to AE
training compared to those with the AGT TT genotype.
Similar to AE training, the overall contribution of clinical sample features on the
BP response to acute AE was large and significant, explaining 55.2% to 82.3% of the
variability. In contrast, the contribution of candidate gene polymorphisms was marginally
significant (P=0.08), but did account for 21.4% to 24.5% of the BP response to acute AE.
The contribution of individual polymorphisms on the BP response to acute AE could not
be determined due to the small number of interventions and observations, and because all
studies were derived from a single trial. In summary, our meta-analytic findings showed
that clinical sample features explained a meaningful proportion of variance in the BP
response to AE, ranging from 59.1% to 71.5% in response to AE training and 55.2% to
82.3% in response to acute AE, while the contribution of candidate gene polymorphisms
modulating the BP response to AE was small and non-significant.
To date (to March 2013), 26 polymorphisms have been reported to be associated
with the BP response to acute and chronic AE (Augeri et al, 2009; Blanchard et al., 2006;
Delmonico et al., 2005; de Luis et al., 2006; Feairheller et al., 2009; Flavell et al., 2006;
Franks et al., 2004; Grove et al., 2007; Hagberg et al., 1999; Hautala et al., 2006; Jones et
al., 2006; Kilpelainen et al., 2008; Pescatello et al., 2007a; Pescatello et al., 2007b;
Pescatello et al., 2009; Rankinen et al., 2000; Rankinen et al., 2002; Rankinen et al. 2007;
Rauramaa et al., 2002; Rivera et al., 2001; Takakura et al., 2006; Vargas et al., 2013;
Zateyschikov et al., 2007; Zhang et al., 2002). Of these, 16 polymorphisms include those
involved with: 1) Renin Angiotensin System (RAS) and/or Renal Function [angiotensin
converting enzyme (ACE) (rs4340), adducin 1 alpha (ADD1) (rs4961), angiotensinogen
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(AGT) (rs699), angiotensin 2 type 1 receptor (AGTR1) (rs5186), and aldosterone synthase
(CYP11B2) (rs1799998); 2) Sympathetic Nervous System [adenosine monophosphate
deaminase 1 (AMPD1) (rs17602729), adrenergic receptor, beta 1 (ADRB1) (rs1801253),
adrenergic receptor, beta 2 (ADRB2) (rs1042714), cholinergic receptor (CHRM2)
(rs324640, rs8191992), guanine nucleotide binding protein system alpha subunit (GNAS)
(rs7121), and guanine nucleotide binding protein, beta polypeptide 3 (GNB3) (rs5443)];
and 3) Nitric Oxide Synthase Pathway and/or Vascular Function [endothelin 1 (EDN1)
(rs5370, rs2070699, rs5369), endothelial nitric oxide synthase (NOS3) (rs2070744), and
transforming growth factor, beta 1 (TGFB1) (rs1800470)]. The remaining 10
polymorphisms are implicated in the etiology of HTN as established or emerging
cardiovascular disease risk factors and include: 1) Dyslipidemia [apolipoprotein (APOE)
(rs7412, rs429358), fatty acid binding protein 2 (FABP2) (rs1799883), and lipoprotein
lipase (LPL) (rs328)]; 2) Obesity [leptin receptor (LEPR) (rs1137100)]; and 3)
Inflammatory Biomarkers [cytochrome b-245 alpha polypeptide (CYBA) (rs4673,
rs1049255), cytochrome P450 superfamily (CYP2D6) (rs1065852), and interleukin 6
receptor (IL6R) (rs2228145).
Of the 26 polymorphisms reported to be associated with the BP response to AE,
16 met our inclusion criteria and were included in our meta-analysis. Of these, only one
polymorphism emerged as significantly associated with the DBP response to exercise in
our meta-analysis, AGT M235T, and explained only 0.3% of the variability. Our finding
confirmed those of Rankinen and Rauramaa et al. in that the AGT M235T polymorphism
was associated with the DBP response to AE training, with greater DBP reductions
observed with the AGT MM genotype than the AGT TT genotype. (Rankinen et al., 2000;
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Rauramaa et al., 2002). Furthermore, this single AGT M235T finding demonstrates the
difficulty in identifying genetic variants that account for the variability in the response of
health/fitness phenotypes to exercise like the BP response to AE.
A proposed mechanism for the influence of the AGT M235T (rs699)
polymorphism on the DBP response to AE training is the reported difference in plasma
AGT levels by genotype (Rankinen et al., 2000; Rauramaa et al., 2002). Jeunemaitre et
al. found resting plasma AGT levels were lower among M versus T allele carriers
(Jeunemaitre et al., 1992). AGT, a substrate of renin that is released by the liver when
blood volume is low, generates angiotensin I that is converted by ACE to angiotensin II,
a potent vasoconstrictor. Angiotensin II increases sodium reabsorption and total
peripheral resistance, thereby elevating BP under resting conditions. Consequently,
Rauramaa et al. postulated higher plasma AGT concentrations among those with the AGT
TT genotype at rest may translate to an over reactivity of the RAS during exercise,
ultimately inducing an overproduction of angiotensin II, and a more potent constriction of
the arterioles that counteract both the vasodilatory and antihypertensive effects of
exercise on BP (Rankinen et al., 2000; Rauramaa et al., 2002).
The most noteworthy finding of this meta-analysis was the clinically meaningful
amount of BP response variability explained by clinical characteristics that included age,
gender and resting BP, accounting for 34.2% to 82.4% of the BP response to AE training.
Bouchard and Rankinen examined individual differences in the BP response to a 20-week
AE training program among 481 sedentary, adult Caucasians from 98 two-generation
families as part of the HERITAGE family study (Bouchard & Rankinen, 2000; Bouchard,
et al., 2012). They found gender and resting SBP explained 1.6% and 32.0% of the SBP
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response to AE training, respectively (Bouchard & Rankinen, 2000; Bouchard, et al.
2012). Likewise, Pescatello and Kulikowich reviewed the ambulatory BP response to
acute dynamic AE in 23 studies that primarily enrolled sedentary, overweight,
non-Hispanic white men and women with Pre-HTN (Pescatello & Kulikowich, 2001).
They found resting BP accounted for 27.0% to 30.0% of the ambulatory SBP and 33.0%
to 37.0% of the ambulatory DBP response to acute AE (Pescatello & Kulikowich, 2001).
Criqui et al. found age explained 15.0% to 44.0% of the peak SBP response to a GXT
among 4,262 men and women in the Lipid Research Clinics Program Prevalence Study
(Criqui et al., 1983). The findings from Bouchard and Rankinen, Pescatello and
Kulikowich, and Criqui et al. are consistent with ours and show that the clinical sample
features of age, gender, and resting BP explain a clinically meaningful proportion of
variance in the BP response to AE.
The present meta-analysis is subject to several limitations. These include the use
of previously reported literature that contained a small number of studies. Despite our
effort to increase the sample size by aggregating the existing literature, our sample
remained underpowered to detect significant associations with individual polymorphisms
occupying ≤ 9 effect size estimates. This was especially true in acute studies, which were
derived from a single trial, making non-independence of acute analyses a threat.
Nonetheless, recent work by Lander et al. suggests that certain epistatic interactions could
be causing underestimations in the amount of explained heritability of complex
phenotypes like the BP response to AE (Zuk, Hechter, Sunyaey, & Lander, 2012). Future
research efforts should therefore move beyond analyses of individual candidate gene
polymorphisms and examine multiple levels of gene regulation via high throughput
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screening involving genes, their regulatory factors, and the proteins they produce to better
explain this phenomenon of missing heritability (Ash, Eicher, & Pescatello, 2012).
The strengths of this study lie in the meta-analytic study design. The use of
meta-analysis allowed us to systematically integrate and quantify the results of fifteen
candidate gene association studies, thereby enabling our ability to circumvent the
limitations of the literature by increasing the sample size and power to detect statistical
associations with the BP response to AE. The overall study quality of included trials was
another strength of this meta-analysis, with mean methodological quality scores of
18.2±2.4 and 15.2±2.1 for acute and chronic trials, respectively. This meta-analysis
satisfied 15 of the 18 items listed on a modified version of the Assessment of Multiple
Systematic Reviews (AMSTAR), a content-validated measurement tool used to assess the
methodological quality of systematic reviews by addressing deficiencies in poorer quality
reviews (Johnson et al. 2013; Shea et al., 2007) [Appendix E]. In addition to satisfying
the items of AMSTAR, this meta-analysis also provided detailed descriptions of each
study’s geographical location, study population (i.e., age, BMI, ethnicity, gender, and BP
status), and exercise intervention (i.e., FITT, supervision, and adherence).
In summary, the purpose of this meta-analysis was to circumvent the limitations
of the literature on candidate gene association exercise studies by increasing the sample
size to detect genetic associations with the BP response to AE. Despite the emergence of
the AGT M235T polymorphism as a promising variant to explore in future research, the
clinical sample features of age, gender, and resting BP explained most of the variability
in the BP response to AE. Our findings reinforce the notion that most genetic variants
explain only a small amount of variability in the response of health/fitness phenotypes to
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exercise, if any. Our findings also indicate that research efforts seeking to explain the
variability of health/fitness phenotypes to exercise such as BP should explore clinical
features known to influence the phenotype of interest, as well as the multiple levels of
gene regulation using high throughput screening in larger, more ethnically diverse
samples of men and women with HTN.
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PubMed Search Strategy

Blood Pressure: ("mean arterial" OR "blood pressure"[mesh] OR "blood pressure" OR "blood
pressures" OR "arterial pressure" OR "arterial pressures" OR hypertension OR hypotension OR
normotension OR hypertensive OR hypotensive OR normotensive OR "systolic pressure" OR
"diastolic pressure" OR "pulse pressure" OR "venous pressure" OR "pressure monitor" OR
hypotension OR "pre hypertension" OR "bp response" OR "bp decrease" OR "bp reduction" OR
"bp monitor" OR "bp monitors" OR "bp measurement")

Exercise: ("exercise"[mesh] OR exercise OR exercises OR running[mesh] OR "bicycle" OR
"bicycles" OR "bicycling" OR walking[mesh] OR treadmill* OR "weight lifting" OR "weight
training" OR "weight bearing" OR "resistance training" OR "strength training" OR "endurance
training" OR "speed training" OR "training duration" OR "training frequency" OR "training
intensity" OR "aerobic endurance")

Randomized Control Trial: ("randomized controlled trial"[pt] OR "nonrandomized controlled"
OR "nonrandomized control" OR controlled clinical trial[pt] OR "randomized controlled
trial"[publication type] OR random allocation[mh] OR clinical trial[pt] OR "comparative study"
OR "comparative studies" OR clinical trials[mh] OR "clinical trial"[tw] OR "latin square"[tw]
OR random*[tw] OR research design[mh:noexp] OR "comparative study"[publication type] OR
"evaluation studies"[publication type] OR "prospective studies"[mh] OR "cross-over
studies"[mh] OR "control"[tw] OR "controlled"[tw])

Gene: ("gene" OR "genes" OR "genotype" OR "genotypes" OR "snp" OR polymorphism* OR
"DNA" OR "minor allele" OR "minor alleles" OR "single nucleotide polymorphism" OR "single
nucleotides polymorphisms" OR genetic*)

Exclusion Search Terms: ("DASH"[tiab] OR "cancer" OR "neoplasms" OR "review"[pt] OR
"fibromyalgia" OR "alzheimers" OR "alzheimer" OR "pregnant" OR "pregnancy" OR
"obesity/drug therapy"[mesh] OR "diet therapy"[mesh] OR "diet therapy"[subheading] OR
"caffeine" OR "eating change" OR "activities of daily living" OR "dehydration" OR "dehydrate"
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OR "dehydrated" OR "dietary salt" OR "epilepsy" OR "influenza" OR "flu" OR "pneumonia"
OR "septicemia" OR "hiv" OR "Acquired Immunodeficiency Syndrome" OR "meningitis" OR
"substance abuse" OR "alcoholism" OR "drug abuse" OR "Cross-Sectional Studies"[MeSH
Terms] OR "Prospective Studies"[MeSH Terms] OR "epidemiology"[Subheading])

Abbreviations: Medical Subject Heading=Mesh; MeSH Terms=mh; Text Word=tw;
Title/Abstract Words=tiab; Publication Type=pt.
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Candidate Gene Meta-Analysis Selection Criteria Checklist
Study ID: __________
Coder: __________

Candidate Gene Meta-Analysis Selection Criteria
Inclusion Criteria
Trials MUST include all of the
following:
An acute and/or chronic aerobic exercise
intervention



A case-control, cross-sectional, or family
based study design (Note: A non-exercise
control or comparison group is required for all
trials; and, a non-exercise control group or
session is required for all acute trials)



Exercise intervention(s) involve all parameters
of the FITT (Note: all FITT parameters
must be satisfied for inclusion):



Frequency



Intensity



Time



Type



Exclusion Criteria
Trials CANNOT include any of the
following:

Cancer survivors
Fibromyalgia



Alzheimer’s disease



Pregnant women



Persons on weight-loss drugs, or
undergoing dietary modifications and/or
therapy



Dehydration studies



Epileptics



Influenza, flu, or pneumonia



Septicemia



HIV/AIDs



Meningitis



A pre-and post-exercise blood pressure
measurement by genotype



A candidate gene polymorphism(s)



Substance abusers



Adults (age 19+)



Alcoholics



Prospective studies



Epidemiologic studies



Note
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CANDIDATE GENE ASSOCIATION STUDIES ON THE BLOOD PRESSURE
RESPONSE TO ACUTE AND CHRONIC AEROBIC EXERCISE
META-ANALYSIS CODING FORM
Revised 8 April 2011
For any missing or unreported data, indicate with “.”

(V1) CODER

________ Coder (Mike = 1, Kara = 2)

Study Information
(V2) ID

________ Study ID # Study Citation (AuthorYearJournal):
________________________________
(Use journal format from PubMed)

(V3) PUB_YR

________ Publication year (consider this missing if unpublished)

(V4) DATA

________ Estimated year of data collection (earliest date for data collection or manuscript
submission/publication; if unpublished and date unknown, use year manuscript was acquired;
for dissertation or thesis, use year)

(V5) LANG.

________ Language of publication
1=English
2=Spanish
3=Japanese
4=Other, specify: __________________________

(V6) SOURCE

________ Source:
1=Journal
2=Book
3=Thesis/Dissertation
4=Conference Paper
5=Unpublished Document

(V7) SCORE

________ Impact Score of the Journal (use ISI Web of Knowledge journal citation reports)

(V8) ________ Notes on intervention within study relevant to coding (if more than one intervention in study)
______________________________________________________________________________________
Sample Characteristics (proportion: 0.0- 1.0)
(V9)
(V10)
(V11)
(V12)
(V13)
(V14)
(V15)
(V16)

ETH
PROP_WH
PROP_BLK
PROP_HISP
PROP_CARIB
PROP_ASIAN
PROP_MIX
EDU

________ Ethnicity reported? 1 = Yes; 0 = No
________ Proportion White; if whole number available: ______
________ Proportion Black; if whole number available: ______
________ Proportion Latino/Hispanic; if whole number available: ______
________ Proportion Caribbean; if whole number available: _____
________ Proportion Asian; if whole number available: ______
________ Proportion Mixed/other; if whole number available: ______
________ Education reported? 1 = Yes; 0 = No
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(V17)
(V18)
(V19)
(V20)
(V21)
(V22)
(V23)

PROP_HS
PROP_COL
PROP_GRAD
SES
PROP_LOW
PROP_MID
PROP_HIGH

________ Proportion high school; if whole number available: ______
________ Proportion college; if whole number available: ______
________ Proportion graduate school; if whole number available: ______
________ SES reported? 1 = Yes; 0 = No
________ Proportion of low SES Low (< 25k)
________ Proportion of middle SES (25k-100k)
________ Proportion of high SES (>100k)

(V24) #FEMALE

________ # of females in sample

(V25) REGION

________ Region of sample
1=American city: __________________
2=Other U.S. general region (city not specified): __________________
3=Canada (city: _______________________)
4=Europe (city: _______________________)
5=South or Central America, Mexico, Caribbean (city: _______________________)
6=Africa (city: _______________________)
7=Asia (city: _______________________)
8=Australia (city: _______________________)

(V26) US_ZIP

________ Zip Code (US Only) _____________

(V27) POP

________ Population
0=Not reported
1=School or college
2=Community, not currently institutionalized; specify source (e.g., cancer clinic including
University cancer treatment facilities):
________________________________________________________
3=Community, institutionalized; specify source (e.g., inpatient cancer treatment center;
currently hospitalized):
________________________________________________________

(V28) ________ Notes on sample characteristics relevant to coding
______________________________________________________________________________________
Risk Characteristics (if SEM, change to SD; SD= SEM *√; use DSTAT to poole variances if applicable)
(V29) AGE
(V30) AGE_SD

________ Mean age of total sample (years)
________ SD for age (years)

(V31) HT
(V32) HT_SD

________ Mean height of total sample (cm)
________ SD of height (cm)

(V33)
(V34)
(V35)
(V36)

________ Mean weight of total sample (kg)
________ SD of weight (kg)
________ Mean waist circumference of total sample (cm)
________ SD of waist circumference (cm)

WT
WT_SD
WAIST
WAIST_SD

(V37) W-H
(V38) W-H_SD
(V39) BMI
(V40)
(V41)
(V42)
(V43)

BMI_SD
BMI_NORM
BMI_OVER
BMI_OBESE1

________ Mean waist-to-hip ratio of total sample
________ SD of waist-to-Hip Ratio
________ Body mass index of total sample (BMI, kg•m-2)
(if calculating, use NHLBI equation)
________ SD of BMI
________ Proportion normal weight (18.5-24.9)
________ Proportion overweight (25.0-29.9)
________ Proportion obese, Class I (30.0-34.9)

50

APPENDIX D
(V44)
(V45)
(V46)
(V47)
(V48)

BMI_OBESE2
BMI_OBESE3
BF%
BF%_SD
BF%_ASS.

________ Proportion obese, Class II (35.0-39.9)
________ Proportion obese, Class III (≥ 40.0)
________ Mean value of body composition of total sample (Body Fat %)
________ SD of body fat %
________ Method of body fat % assessment
1=Skinfold thickness
2=Hydrostatic weighing
3=Bioelectrical impedance, specify: _________________
4=Air displacement plethysmography, specify: _________________
5=Dual energy x-ray absorptiometry (DEXA), specify: _________________
6=Other, specify: __________________

(V49) PROP_HD

________ Proportion of total sample with history of heart disease in immediate
family members before age 55; if whole number available ______

(V50) PROP_ HTN

________ Proportion of total sample with hypertension in immediate family
members; if whole number available ______

(V51) DISEASE

________ Known disease(s) or chronic condition(s) of total sample
0= Subjects were free of disease(s)/chronic condition(s)
1= Pre-Hypertension
2= Hypertension, specify stage: __________________________
3= Cardiovascular disease(s) (coronary artery disease, peripheral artery disease,
congestive heart failure, myocardial infarction)
4= Stroke
5= Diabetes
6= Metabolic Syndrome (MetS)
7= Arthritis
8= Other, specify: __________________
9= Multiple, specify #s:__________________

(V52) CHF

________ If congestive heart failure, indicate functional classification
(according to NYHA criteria)
0= Not applicable
1= Class I
2= Class II
3= Class III
4= Class IV
5= Multiple, specify #’s______________

(V53) MetS

________ If Metabolic Syndrome (MetS), what grouping system was used to define
0= Not applicable
1= Specify: __________________

(V54) PROP_SED

________ Proportion of sample that was sedentary (≤ 2d•wk-1 of regular physical
activity); if whole number available ______

(V55) MED

________ Medication use (0=No, 1= Yes)
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(V56) MED_TYPE

________ Medication Type
1= β Blockers
2= Nitrates
3= Calcium Channel Blockers
4= Angiotensin Converting Enzyme (ACE) Inhibitors
5= Diuretics
6= Vasodilators, non-adrenergic
7= NSAIDs
8= Aspirin
9= Other, specify: ________________
10= Multiple, specify numbers: ________________

(V57) O/C_USE

________ Oral Contraceptive use (0=No, 1= Yes)

(V58)
(V59)
(V60)
(V61)

CAFFEINE_USE
CAFFEINE_DR
CAFFEINE_WK
PROP_CAF

________ Number of days per week of caffeine consumption
________ Number of caffeinated beverages per day
________ Number of caffeinated beverages per week
________ Proportion of sample with regular caffeine consumption; if whole
number available ______

(V62)
(V63)
(V64)
(V65)

ETOH_USE
ETOH_DR
ETOH_WK
PROP_ETOH

________ Number of days per week of alcohol consumption
________ Number of alcoholic drinks per day
________ Number of alcoholic drinks per week
________ Proportion of sample reporting regular alcohol consumption; if whole
number available ______

(V66)
(V67)
(V68)
(V69)

SMOKING
SMOKING_YRS
SMOKE_PACK
PROP_SMOKE

________Currently smoking, or smoked within last 6 months (0= No, 1= Yes)
________Number of years smoking
________Number of packs per week (calculate in data base pack/ year)
________Proportion of sample currently smoking or smoked within the last 6
months? ; if whole number available ______

(V70) ________ Notes on risk characteristics relevant to coding
______________________________________________________________________________________
Methods & Design
(V71) RECRUIT

________ Recruitment method
1=Self-selected from community (via flyers, community centers, etc.)
2=Recruited through clinical contact
3=Recruited through hospital
4=Other, specify: __________

(V72) CON_GRP

________ Type of control group used
1= Random assignment of individuals to conditions including a non-exercise control
group
2= Random assignment of individuals to conditions including a non-exercise control
session
3= Random assignment of individuals to conditions including a control group of
stretching or yoga
4= Other, specify:
______________________________________________________________________

(V73) #F/U

________ Number of follow-ups: ______________________________
(0=acute, 1= pre/post design)

52

APPENDIX D
________ Interval of follow-ups: _______________________________
(0=acute,1= pre/post design)
(# of follow-ups refer to the assessments completed post intervention, i.e. 3, 6, 12 months post study)

(V74) F/U_INT.

(V75) ________ Notes on methods & study design relevant to coding
______________________________________________________________________________________
Mechanism
(V76) MECH

________ Mechanism
0= None reported
1= Genetic
2= Neural
3= Vascular
4= Renal
5= Other, specify:________________
6= Multiple, specify #s:___________

(V77) ________ Notes on mechanisms relevant to coding
______________________________________________________________________________________
(V78) BIO PATH

________ Major Biological Pathway
0= None
1= Renal/Renin Angiotensin System
2= Sympathetic Nervous System
3= Nitric Oxide Synthase Pathway
4= Energy Metabolism
5= Inflammation/Thrombosis/ Hemostasis
6= Other

(V79) ________ Notes on mechanisms relevant to coding

______________________________________________________________________________________

53

APPENDIX D
Study Quality
Downs and Black tool (Downs and Black 1998)
1. Is the hypothesis/aim/objective of the study clearly described?
Yes
1
No
0
2. Are the main outcomes to be measured clearly described in the Introduction or Methods section?
Yes
1
No
0
3. Are the characteristics of the patients included in the study clearly described?
Yes
1
No
0
4. Are the interventions of interest clearly described?
Yes
1
No
0
5. Are the distributions of principal confounders in each group of subjects to be compared clearly described?
Yes
2
Partially
1
No
0
6. Are the main findings of the study clearly described?
Yes
1
No
0
7. Does the study provide estimates of the random variability in the data for the main outcomes?
Yes
1
No
0
8. Have all important adverse events that may be a consequence of the intervention been reported?
Yes
1
No
0
9. Have the characteristics of patients lost to follow-up been described?
Yes
1
No
0
10. Have actual probability values been reported (e.g. 0.035 rather than <0.05) for the main outcomes except where the
probability value is less than 0.001?
Yes
1
No
0
External validity
All the following criteria attempt to address the representativeness of the findings of the study and whether they may be
generalised to the population from which the study subjects were derived.
11. Were the subjects asked to participate in the study representative of the entire population from which they were recruited?
Yes
1
No
0
Unable to determine
0
12. Were those subjects who were prepared to participate representative of the entire population from which they were
recruited?
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Yes
No
Unable to determine

1
0
0

13. Were the staff, places, and facilities where the patients were treated, representative of the treatment the majority of patients
receive?
Yes
1
No
0
Unable to determine
0
Internal validity - bias
14. Was an attempt made to blind study subjects to the intervention they have received?
For studies where the patients would have no way of knowing which intervention they received, this should be answered yes.
Yes
No
Unable to determine

1
0
0

15. Was an attempt made to blind those measuring the main outcomes of the intervention?
Yes
No
Unable to determine

1
0
0

16. If any of the results of the study were based on “data dredging”, was this made clear?
Yes
1
No
0
Unable to determine
0
17. In trials and cohort studies, do the analyses adjust for different lengths of follow-up of patients, or in case-control studies, is
the time period between the intervention and outcome the same for cases and controls?
Yes
1
No
0
Unable to determine
0
18. Were the statistical tests used to assess the main outcomes appropriate?
Yes
1
No
0
Unable to determine
0
19. Was compliance with the intervention/s reliable?
Yes
1
No
0
Unable to determine
0
21. Were the patients in different intervention groups (trials and cohort studies) or were the cases and controls (case-control
studies) recruited from the same population?
Yes
1
No
0
Unable to determine
0
22. Were study subjects in different intervention groups (trials and cohort studies) or were the cases and controls (case-control
studies) recruited over the same period of time?
Yes
1
No
0
Unable to determine
0
23. Were study subjects randomised to intervention groups?
Yes
1
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No
Unable to determine

0
0

24. Was the randomised intervention assignment concealed from both patients and health care staff until recruitment was
complete and irrevocable?
Yes
1
No
0
Unable to determine
0
25. Was there adequate adjustment for confounding in the analyses from which the main findings were drawn?
Yes
1
No
0
Unable to determine
0
26. Were losses of patients to follow-up taken into account?
Yes
1
No
0
Unable to determine
0
Power
27. Did the study have sufficient power to detect a clinically important effect where the probability value for a difference being
due to chance is less than 5%? Sample sizes have been calculated to detect a difference of x% and y%.
Size of smallest intervention group
<n1
n1- n2
n3- n4
n5- n6
n7- n8
n8+

A
B
C
D
E
F

Total Score:
(V80)

0
1
2
3
4
5



STUDY_QUAL ________ Total study quality score (out of a possible 31 points)

Experiment/Intervention Conditions
EXPERIMENT ________ Experimental condition(s)
Independent groups (between-subjects design; participant only experiences one
condition)
1= Non-exercise control/comparison + one experimental group
2= Non-exercise control/comparison + two experimental groups
3= Non-exercise control/comparison + three experimental groups
Non-Independent groups (within-subjects design; participant experiences more than
one condition)
4= Non-exercise control/comparison + one experimental condition
5= Non-exercise control/comparison + two experimental conditions
6= Non-exercise control/comparison + three experimental conditions

(V81)
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(V82) EXP_SETTING

________ Setting of Experiment/ Intervention
1= Hospital
2= Clinic
3= Academic Research Laboratory
4= Fitness Center, Gym
5= Other, specify: _____________________________
6= Multiple, specify: _____________________________

(V83) PERSP

________ Theoretical perspective:
0= None specified
1= Psychological
2= Other, specify __________________________

(V84)

BEHAV_TECH ________ Behavioral technique used in study?
0= None
1= Yes, specify (positive reinforcement, modeling, contingency management, exercise
and lifestyle information provided, etc.)

(V85)

INTER_LVL

________ Level of intervention used in the study
1=Primarily one-on-one (e.g., individual counseling sessions)
2=Small group processes (interaction between leader and group, and group members)
3=Supervised session(s)
4=Unsupervised session(s)
5=Multiply, specify #’s: ________________________________

(V86) ________ Notes on experiment/intervention conditions relevant to coding
______________________________________________________________________________________
Candidate Gene Polymorphisms
(V87)

QUANT_GENES ________ Number of candidate genes examined

(V88)

GENE_NAME

________ Name of candidate gene (s) examined
________
________
________
________
________

(V89)

QUANT_SNP

________ Number of SNPs examined

(V90)

SNP_TEST

________ Specific SNP(s) examined (include RS #’s if available)
________
________
________
________

(V91)

CHROM_NUMB ________ Chromosome number(s)
________
________
________
________
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(V92)

(V93)

CHROM_BAND ________ Chromosome band(s)
________
________
________
________
CHROM_SUB ________ Chromosome sub-band(s)
________
________
________
________
________Study design
1=Case-control
2=Cross-sectional
3=Family-based
________ Rationale for SNP selection
1=Allele frequency
2=Literature search
3=Follow-up to GWAS

(V94)

DESIGN

(V95)

SNP_RATION

(V96)

SOURCE

________ Source of samples
1=Clinic
2=Population
3=Athletes

(V97)

TECH

________ Sampling technique(s)
1=Buccal swab
2=Blood

(V98)

COMB_MODEL ________ Combination model
1=Dominant
2=Recessive
3=Co-dominant
4=Incomplete/Semi-dominant

(V99)

OUTCOME

(V100) MAJ_FREQ
(V112a)

(V112b)
(V112c)
(V101) MIN_FREQ
(V112a)

(V112b)

________ Outcome
1=Positive
2=Negative
3=Trend
________ Major Allele Frequency
1=Stated in paper
2=Calculated from paper
3=Obtained from authors
4=Unknown
________ Case frequency
________ Control frequency
________ Minor Allele Frequency
1=Stated in paper
2=Calculated from paper
3=Obtained from authors
4= Unknown
________ Case frequency
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(V112c)

________ Control frequency

(V102) HWE

________ Hardy Weinberg Equilibrium
1=Yes
2=No
3=Not stated

(V103) LD

________ Linkage Disequilibrium
1=Low (<. 5)
2=Marginal (.6-.8)
3=High (>.8)
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CANDIDATE GENE CODING INFORMATION
For Polymorphisms Studied by at Least One Paper
List interventions from LOWEST intensity to HIGHEST
intensity
AEROBIC
AEROBIC
AEROBIC
CONTROL
#1
#2
#3
(V104) Subgroup (i.e. men, women, hypertensive, normotensive, white, black, etc.), specify:
VARIABLE

________________(0=Not applicable)
(V105) GENE_NAME Name of candidate genes examined: ________________
(V106) SNP_TEST Specific SNP examined (include RS #’s if available): ________________
(V107) CHROM_NUMB Chromosome number________________
(V108) CHROM_BAND Chromosome band________________
(V109) CHROM_SUB Chromosome sub-band________________
(V110) FUNCT Function (1=missense, 2=nonsense, 3=coding synonymous, 4=neargene-3, 5=neargene-5, 6=3’UTR, 7=5’-UTR, 8=intron) ________________
(V111) # PART_BEG
# of participants at beginning of intervention
(V112) # PART_END
# of participants at end of intervention
(V113) # PART_LOST
# of participants lost during intervention
(V114) ADHERENCE
Mean participant adherence

 
) x100
(
   
(V115) EX_INTENSITY
Exercise intensity (specify method used to
calculate intensity) 0=Control/Non-exercise
comparison group/session (Note. If ranges are
reported, compute the mean or average value)
(V116) EX_TYPE
Exercise modality
0=Control (non-exercise comparison)
1= Aerobic, treadmill
2= Aerobic, cycle ergometer
3= Other, specify: _______________
4= Multiple, specify numbers: ___________
(V117) EX_LENGTH
Length of intervention (weeks) 0=Acute
(V118) FREQ_SESSION
Exercise Frequency (sessions per week)
0=Acute
(V119) FREQ_WK
Exercise Frequency (min per week) 0=Acute
(V120) EX_TOTAL
Total Exercise Duration (min per week)
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(V121) EX_W/UP
Warm-up (min per session)
(V122) EX_TIME
Exercise (min per session)
(V123) EX_C/D
Cool down (min per session)
(V124) VAR_ALTER
Study Variable manipulated
0= Control/ Non-exercise comparison
1=Exercise duration
2=Exercise intensity
3=Exercise frequency
4=Exercise modality
5=Exercise volume
6=Exercise vs. Control
7=Multiple, specify #s: _______________
(V125) ∆VO2
VO2max change (specify method used to
calculate intensity) 0= Acute
(V126) BP_ASSESS
BP Measurement
1=Manual
2=Ambulatory (ABP), hrs monitored: _____
3=Automated
4=Multiple, specify #s__________
(V127) BP_POSITION
BP Measurement Position
1=Seated
2=Standing
3=Supine
4=Multiple, specify #s________________
(V128) BP_BASE
Duration prior to baseline BP assessment
(min)
(insert continuous variable, or “.” if none or
missing)
(V129) SBP_INITIAL
Initial SBP (mmHg)
(V130) INITIAL_SD
SD of Initial SBP (mmHg)
(V131) SBP_POST
Post SBP (mm Hg)
(V132) POST_SD
SD of Post SBP (mmHg)
(V133) SBP_AB∆
Absolute change SBP (mmHg)
(if not calculated, insert “.”and calculate in
spreadsheet)
(V134) AB∆_SD
SD of Absolute change SBP (mmHg)
(V135) DBP_INITIAL
Initial DBP (mmHg)
(V136) INITIAL _SD
SD of Initial DBP (mmHg)
(V137) DBP_POST
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Post DBP (mmHg)
(V138) POST_SD
SD of Post DBP (mmHg)
(V139) DBP_AB∆
Absolute change DBP (mmHg)
(if not calculated, insert “.”and calculate in
spreadsheet)
(V140) AB∆_SD
SD of Absolute change DBP (mmHg)
(V141) BP_POST
Time of Post BP assessment (min)
(insert continuous variable, or “.” if none or
missing)
(V142) MAP
MAP (mm Hg) (if not calculated, insert
“.”and calculate in spreadsheet)
List interventions from LOWEST intensity to HIGHEST
intensity
STRENGTH STRENGTH STRENGTH
CONTROL
#1
#2
#3
(V143) Subgroup (i.e. men, women, hypertensive, normotensive, white, black, etc.), specify: ________________
VARIABLE

(0=Not Applicable)
(V144) GENE_NAME Name of candidate genes tested: ________________
(V145) SNP_TEST Specific SNP examined (include RS #’s if available): ________________
(V146) CHROM_NUMB Chromosome number________________
(V147) CHROM_BAND Chromosome band________________
(V148) CHROM_SUB Chromosome sub-band________________
(V149) FUNCT Function (1=missense, 2=nonsense, 3=coding synonymous, 4=neargene-3, 5=neargene-5, 6=3’UTR, 7=5’-UTR, 8=intron) ________________
(V150) #PART_BEG
# of participants at beginning of intervention
(V151) #PART_END
# of participants at end of intervention
(V152) #PART_LOST
# of participants lost during intervention
(V153) ADHERENCE
Mean participant adherence

 
(
)*100
   
(V154) EX_INTENSITY
Exercise intensity (specify method used to
calculate intensity) 0=Control/Non-exercise
comparison group/session (Note. If ranges are
reported, compute the mean or average value)
(V155) EX_TYPE
Exercise modality
0=Control (non-exercise comparison)
1=Dynamic resistance training (free weights)
2=Dynamic resistance training (machine
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weights)
3=Isometric resistance training
4=Other, specify: _______________
5=Multiple, specify numbers: ___________
(V156) EX_LENGTH
Length of intervention (weeks) 0=Acute
(V157) FREQ_SESSION
Exercise Frequency (sessions per week)
0=Acute
(V158) FREQ_WK
Exercise Frequency (min per week) 0=Acute
(V159) EX_TOTAL
Total Exercise Duration (min per week)
(V160) EX_W/UP
Warm-up (min per session)
(V161) EX_TIME
Exercise (min per session)
(V162) EX_C/D
Cool down (min per session)
(V163) EX_SETS
Total # of sets performed in session
(V164) EX_REPS
Total # of reps performed in one set
(V165) VAR_ALTER
Study Variable manipulated
0=Control/Non-exercise comparison
1=Exercise duration
2=Exercise intensity
3=Exercise frequency
4=Exercise modality
5=Exercise volume
6=Exercise vs. Control
7=Multiple, specify #s: _______________
(V166) ∆VO2
VO2max change (specify method used to
calculate intensity) 0=Acute
(V167) BP_ASSESS
BP Measurement
1=Manual
2=Ambulatory (ABP), hrs monitored: _____
3=Automated
4=Multiple, specify #s__________
(V168) BP_POSITION
BP Measurement Position
1=Seated
2=Standing
3=Supine
4=Multiple, specify #s________________
(V169) BP_BASE
Duration prior to baseline BP assessment
(min)
(insert continuous variable, or “.” if none or
missing)
(V170) SBP_INITIAL
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Initial SBP (mmHg)
(V171) INITIAL_SD
SD of Initial SBP (mmHg)
(V172) SBP_POST
Post SBP (mmHg)
(V173) POST_SD
SD of Post SBP (mmHg)
(V174) SBP_AB∆
Absolute change SBP (mmHg)
(if not calculated, insert “.”and calculate in
spreadsheet)
(V175) AB∆_SD
SD of Absolute change SBP (mmHg)
(V176) DBP_INITIAL
Initial DBP (mmHg)
(V177) INITIAL _SD
SD of Initial DBP (mmHg)
(V178) DBP_POST
Post DBP (mmHg)
(V179) POST_SD
SD of Post DBP (mmHg)
(V180) DBP_AB∆
Absolute change DBP (mmHg)
(if not calculated, insert “.”and calculate in
spreadsheet)
(V181) AB∆_SD
SD of Absolute change DBP (mmHg)
(V182) BP_POST
Time of Post BP assessment (min)
(insert continuous variable, or “.” if none or
missing)
(V183) MAP
MAP (mmHg) (if not calculated, insert
“.”and calculate in spreadsheet)
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Statistical Analyses

Statistical Variable: Homozygous
Common Genotype (AA)

Control

Exercise group 1
(specify: ______________)

Exercise group 2
(specify:
______________)

(V184) ____Method of analysis (1=Dominant model, 2=Recessive model, 3=Risk allele)
(V185) ____Multiple testing correction (1=Yes, 2=Yes but questionable, 3=No)
(V186) SBP Mean & SD
(0=if not calculated)
(V187) DBP Mean & SD
(0=if not calculated)
(V188) SBP Correlation
Coefficient
(0=if not calculated)
(V189) DBP Correlation
Coefficient
(0=if not calculated)
(V190) SBP Odds ratio
(0=if not calculated)
(V191) DBP Odds ratio
(0=if not calculated)
(V192) SBP R-squared value
(0=if not calculated)
(V193) DBP R-squared value
(0=if not calculated)
(V194) SBP Chi-Squared Result
(0=if not calculated)
(V195) DBP Chi-Squared Result
(0=if not calculated)
(V196) SBP P-Value
(0=if not calculated)
(V197) DBP P-Value
(0=if not calculated)
(V198) SBP F Statistic
(0=if not calculated)
(V199) DBP F Statistic
(0=if not calculated)
(V200) SBP Confidence Interval
(0=if not calculated)
(V201) DBP Confidence Interval
(0=if not calculated)
(V202) SBP Other statistical
outcome, specify:_______
(V203) DBP Other statistical
outcome, specify: _______
(V204)

________ Notes on statistical analyses relevant to coding

_____________________________________________________________________________________
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Statistical Variable:
Heterozygous Genotype (AB)

Control

Exercise group 1
(specify:______________)

Exercise group 2
(specify:______________)

(V205) ____Method of analysis (1=Dominant model, 2=Recessive model, 3=Risk allele)
(V206) ____Multiple testing correction (1=Yes, 2=Yes but questionable, 3=No)
(V207) SBP Mean & SD
(0=if not calculated)
(V208) DBP Mean & SD
(0=if not calculated)
(V209) SBP Correlation
Coefficient
(0=if not calculated)
(V210) DBP Correlation
Coefficient
(0=if not calculated)
(V211) SBP Odds ratio
(0=if not calculated)
(V212) DBP Odds ratio
(0=if not calculated)
(V213) SBP R-squared value
(0=if not calculated)
(V214) DBP R-squared value
(0=if not calculated)
(V215) SBP Chi-Squared
Result
(0=if not calculated)
(V216) DBP Chi-Squared
Result
(0=if not calculated)
(V217) SBP P-Value
(0=if not calculated)
(V218) DBP P-Value
(0=if not calculated)
(V219) SBP F Statistic
(0=if not calculated)
(V220) DBP F Statistic
(0=if not calculated)
(V221) SBP Confidence
Interval
(0=if not calculated)
(V222) DBP Confidence
Interval
(0=if not calculated)
(V223) SBP Other statistical
outcome, specify: ____
(V224) DBP Other statistical
outcome, specify: ____
(V225)

________ Notes on statistical analyses relevant to coding

_____________________________________________________________________________________
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Statistical Variable:
Homozygous Minor Genotype
(BB)

Control

Exercise group 1
(specify:______________)

Exercise group 2
(specify:______________)

(V226) ____Method of analysis (1=Dominant model, 2=Recessive model, 3=Risk allele)
(V227) ____Multiple testing correction (1=Yes, 2=Yes but questionable, 3=No)
(V228) SBP Mean & SD
(0=if not calculated)
(V229) DBP Mean & SD
(0=if not calculated)
(V230) SBP Correlation
Coefficient
(0=if not calculated)
(V231) DBP Correlation
Coefficient
(0=if not calculated)
(V232) SBP Odds ratio
(0=if not calculated)
(V233) DBP Odds ratio
(0=if not calculated)
(V234) SBP R-squared value
(0=if not calculated)
(V235) DBP R-squared value
(0=if not calculated)
(V236) SBP Chi-Squared
Result
(0=if not calculated)
(V237) DBP Chi-Squared
Result
(0=if not calculated)
(V238) SBP P-Value
(0=if not calculated)
(V239) DBP P-Value
(0=if not calculated)
(V240) SBP F Statistic
(0=if not calculated)
(V241) DBP F Statistic
(0=if not calculated)
(V242) SBP Confidence
Interval
(0=if not calculated)
(V243) DBP Confidence
Interval
(0=if not calculated)
(V244) SBP Other statistical
outcome, specify: ____
(V245) DBP Other statistical
outcome, specify: ____
(V246)

________ Notes on statistical analyses relevant to coding

_____________________________________________________________________________________
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ExBP Meta-Analysis Quality
Question
1. Was an ‘a priori’ design provided?
2. Were population variables defined and
considered in the methods?
3. Was there duplicate study selection and
data extraction?
4. Was a comprehensive literature search
performed?
5. Is it possible to replicate the search?

6. Did the inclusion criteria permit grey
literature?
7. Was a list of studies (included and
excluded) provided?
8. Were the characteristics of the included
studies provided?

9. Was FITT defined for each study and
examined in relation to BP effect sizes?
10. Was the scientific quality of the included
studies assessed and documented?

11. Was the scientific quality of the included
studies used appropriately in formulating
conclusions?
12. Did results depend on study quality,
either overall, or in interaction with
moderators?
13. Were the methods used to combine the
findings of studies appropriate?

14. Was the effect size index chosen
justified, statistically?

M-a (Author(s), Year, Journal):
Rationale for Question

Coder:
Score

Notes (If Any)

The research question and inclusion criteria should be established before the conduct of the
review. Is it stated that these were finalized before commencing the review?
Blood pressure is related to patient (age, biological sex, ethnicity, BMI) and clinical (chronic
disease, medication use) variables.

AMSTAR#1-modified

There should be at least two independent data extractors and a consensus procedure for
disagreements should be in place; minimum moderate reliability (e.g., r=.70) should be
reported.
At least two electronic sources should be searched. The report must include years and
databases used (e.g. Central, EMBASE, and MEDLINE). All searches should be supplemented
by consulting current contents, reviews, textbooks, specialized registers, or experts in the
particular field of study, and by reviewing the references in the studies found.
The Method or Supplementary Materials should make it possible for a second party to replicate
the search, including all databases, search terms, and operators. Key words and/or MESH
terms must be stated or available from the authors and where feasible the search strategy
should be provided. If authors report MeSH terms were used for searching, they must be stated
in methods OR provided in supplementary material to be considered a “2.” A note to contact the
author for complete search strategy is also acceptable.
The authors should state that they searched for reports regardless of their publication type. The
authors should state whether or not they excluded any reports (from the systematic review),
based on their publication status, language etc.
A list of included and excluded studies should be provided. A descriptive summary of reasons
for excluding studies should be provided such as in a QUORUM or PRISMA figure.

AMSTAR#2

AMSTAR#3-modified

AMSTAR#3-modified

AMSTAR#4-modified

AMSTAR#5-modified

In an aggregated form such as a table, data from the original studies should be provided on the
participants, interventions and outcomes. The ranges of characteristics in all the studies
analyzed e.g. age, race, sex, relevant socioeconomic data, disease status, duration, severity, or
diseases. Data must be presented for each study individually in a table to receive a score of “2”
simply providing population or study description in the text is not sufficient.
Frequency, Intensity, Time and Type (FITT) of exercise define major components of exercise
and logically relate to BP changes. Results need not show significant moderation patterns.

AMSTAR#6

‘A priori’ methods of assessment should be provided (e.g., for effectiveness studies if the
author(s) chose to include only randomized, double-blind, placebo controlled studies, or
allocation concealment as inclusion criteria); for other types of studies alternative items will be
relevant. If study quality was assessed and documented with a tool and/ or scale, choose 2; if it
was discussed in text only, choose 1; if it was not documented at all, choose 0
The results of the methodological rigor and scientific quality of the included studies must be
considered in the analysis and the conclusions of the review, and explicitly stated in formulating
recommendations to receive a “2” (i.e., study quality scores related to outcomes, discussion of
individual study quality and its relation to outcome). Simply stating inclusion of specific study
design (e.g., RCTs) because they are typically of higher quality is not sufficient.
Studies with higher methodological rigor (e.g., with a scale such as PEDro) should yield clearer
findings, other factors equal.

AMSTAR#7

For the pooled results, a test should be done to ensure the studies were combinable, to assess
their homogeneity (i.e., χ2 for homogeneity or I²). If heterogeneity exists, random-effects
assumptions should be incorporated and/or the clinical appropriateness of combining should be
taken into consideration (i.e. is it sensible to combine?). If a test of homogeneity was
conducted, the X2 or I2 value is reported, and they report the statistical assumptions (i.e., fixed
vs. random-effects) choose 2; if they report some of the information but not all, choose 1; if they
do not discuss homogeneity at all, choose 0.
Comparisons of studies’ results may be biased in the face of uncontrolled variables (e.g.,
standard deviations related to mm/Hg for SBP or DBP that vary widely across studies). If

AMSTAR#9-modified

AMSTAR#8

APPENDIX

15. Was individual-level meta-analysis used
for moderator analyses?
16. Were clinical ramifications clearly
addressed?
17. Was the likelihood of publication bias
assessed?
18. Was the conflict of interest stated?

authors provide ES equation/ explain their ES calculation and relate it to the various study
designs and methods of reporting results, choose 2; if authors provide ES information but do
not relate it to various study designs, choose 1; if ES is not discussed at all, choose 0.
The authors should state whether or not they obtained original data from the study authors
when performing moderator analyses.
The results and discussion should clearly lend themselves to informing clinical practice in
relation to particular populations and health problems. Reports must provide clear clinical
ramification or recommendation (i.e., what does this study add?) Simply re-stating what is
known in the literature, or introduction material is not adequate.
Asymmetries in effect sizes are examined as evidence of potential publication bias and includes
a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests
(e.g., Egger regression test).
Potential sources of support or conflict should be clearly acknowledged in both the systematic
review and the included studies.
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